Novo Nordisk rose as much as 4% after England’s drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes.

Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity.

The new recommendation the National Institute for Health and Care Excellence (NICE), England’s drug price regulator, will significantly expand access to Wegovy on the country’s National Health Service (NHS).

The regulator, which assesses a medicine’s cost-effectiveness, recommended semaglutide, the active ingredient in Wegovy and diabetes treatment Ozempic, as an option for adults who have previously had a heart attack, a stroke, or a serious circulation problem in the legs and who have a body mass index (BMI) of at least 27.

Novo’s Copenhagen-listed shares were last seen up 2% in morning trading, paring some earlier gains. The pan-European blue-chip index Stoxx 600 was up 2.1%.

This is a breaking news story. Please refresh for updates.

President Donald Trump on Monday said he thinks he will have the “honor” of “taking Cuba,” speaking during an executive order signing at the White House.

“Whether I free it, take it, I think I can do anything I want with it,” Trump told reporters in the Oval Office with Vice President JD Vance standing behind him. “They’re a very weakened nation right now.”

The president’s comments on taking Cuba come as he carries out a war in Iran that is stretching into its third week. Trump has encouraged the people of Iran to depose their government in that conflict, one of a litany of reasons he has given for starting the war.

Trump recently suggested he will turn his sights to Cuba after the U.S. achieves its aims in Iran. He has threatened a “friendly takeover” of the Caribbean nation, which has been an adversary of the U.S. for decades except for a brief thaw when Barack Obama was president.

The Cuba threats are the latest example of Trump’s more aggressive foreign policy during his second term in the White House. In addition to the war in Iran, Trump ordered a military operation that captured the Venezuelan leader Nicolás Maduro and has made repeated overtures to acquire Greenland, the Arctic island territory of Denmark. Denmark has repeatedly said Greenland is not for sale.

The White House has effectively blockaded Havana from Venezuelan oil after Maduro’s capture. That has caused an energy and economic crisis in the island country.

Cuba confirmed it was speaking with the Trump administration about a potential solution last week. Trump also confirmed the talks on Monday.

“I can tell you that they’re talking to us; it’s a failed nation, they have no oil, they have no nothing,” Trump said. “They have nice land.”

Denmark’s energy minister urged citizens of the Scandinavian country to cut back on energy use and ditch cars as the price of oil continues to skyrocket amid the Middle East conflict.

Lars Aagaard, Denmark’s minister for climate, energy, and utilities, said Wednesday that the ongoing war between the U.S. and Iran has driven the country to lean on its oil reserves in light of “towering oil prices” with no end to the conflict in sight.

“What the Danes should please, please, please do is that if there is any energy consumption that you can do without, if it is not strictly necessary to drive the car, then don’t do it,” he said in an interview with local broadcaster DR, translated by Google.

If Denmark saves energy in the near future, there will be two positive effects that can be felt both by citizens and the government, he said.

“Firstly, it can be felt in the private wallet, and secondly, it can help stretch our reserves so that they last longer,” Aagaard said.

Similar warnings have been issued across countries worldwide. In the U.K., motoring groups such as the AA have called on drivers to cut “non-essential journeys,” and change their driving style to conserve fuel.

Vietnam’s Ministry for Industry and Trade encouraged businesses to adopt remote working arrangements and reduce travel and transport demand to ensure national energy security.

Meanwhile, the Philippine government implemented a temporary four-day workweek in certain executive branches to conserve energy and reduce fuel use.

Concerns over oil prices have remained elevated this week, as oil shipments through the Strait of Hormuz ground to a halt due to the threat of Iranian attacks on vessels. A potential inflation spike could follow if the passage remains closed, and threatens to raise the cost of living, from petrol to groceries.

Oil prices jumped over 8% to more than $100 per barrel earlier on Thursday. The West Texas Intermediate was last up 4.6% to $91 per barrel, while global benchmark Brent was trading nearly 5% higher at $96.

To assuage these fears, the International Energy Agency on Wednesday agreed to release 400 million barrels of oil to address the supply disruption triggered by the Iran war.

The IEA, which represents 32 member countries across Europe, North America, and northeast Asia, said the reserves would be released over a specific time frame, depending on the needs of its member countries.

Meanwhile, the U.S announced that it would release 172 million barrels from its Strategic Petroleum Reserve, with shipments expected to begin next week and take roughly 120 days to complete.

Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company.

But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago.

Pricing pressure, fierce competition, and pipeline setbacks have all hit the Danish drugmaker in recent months.

Despite being first to launch a GLP-1 drug for weight loss, Novo’s market share has eroded, and the company now only captures about 40% of the market, while rival Eli Lilly holds 60%, according to most estimates.

Novo is clear-eyed about the challenges it faces, especially around pricing. After the company pre-released its 2026 forecast earlier this month and predicted declining sales, CEO Mike Doustdar told CNBC: “People should expect that it goes down before it comes back up.”

He’s repeatedly said that new medicines, the Wegovy pill, and increased volumes will drive long-term growth.

These charts show the scale of the challenges Novo is facing.

Novo Nordisk is often referred to as a diabetes and obesity pure play. Its portfolio included six branded drugs with annual sales of at least $1 billion in 2025, fewer than comparable current and future rivals.

Eli Lilly boasts eight so-called blockbuster drugs, and its portfolio also includes oncology and gene therapies.

The combined sales of Ozempic and Wegovy, Novo’s two biggest drugs, amounted to about $32 billion, or about 67% of total sales, last year. Combined sales of Lilly’s two biggest drugs, Mounjaro and Zepbound, were about $37 billion, or about 56% of the company’s total sales over the same period.

Novo also sells insulin, including blockbusters Tresiba and NovoRapid, as well as some drugs for rare diseases like hemophilia, but none come close to bringing in what its GLP-1 drugs do.

Among large-cap pharma companies hoping to enter the market for weight loss drugs in the coming years, such as AstraZeneca, Roche, Amgen, and Pfizer, through its acquisition of Metsera, the number of blockbuster drugs was significantly higher.

Novo Nordisk has also come under pressure as prices for GLP-1 drugs are coming down in its most important market, the U.S.

The U.S. has accounted for more than half of Novo’s total sales since 2023, and falling prices there are weighing on both the company’s topline and profitability. Last year, Novo and Lilly reached a deal with the Trump administration to lower prices on their GLP-1 drugs on Medicare and Medicaid and offer the treatments directly to consumers at a discount.

“In 2026, Novo Nordisk will face pricing headwinds in an increasingly competitive market,” said CEO Mike Doustdar, as the company’s full-year earnings report was published earlier this month.

Novo stock is down 75% since peaking at just over 1,000 Danish kroner a share in mid-2024.

The stock is up a little over 10% over the last five years. That compares to Eli Lilly’s 400% rise and the European blue-chip index Stoxx 600‘s 55% gain over the same period.

Investors were last rattled on Monday when Novo reported disappointing results of a trial pitting its next-generation weight loss drug, CagriSema, against Eli Lilly’s tirzepatide, also known as Zepbound, sending the stock down over 16% on the day.

“Confidence in the share is at rock bottom,” said Jyske Bank analyst Henrik Hallengreen Laustsen on Tuesday.

Earlier this month, Novo Nordisk said it expected sales and profits to drop by between 5% and 13% in 2026. If that comes to be true, it would be the first time annual sales have declined since 2017, in local currencies.

Analysts surveyed by FactSet expect sales to come in about 8% lower in 2026 compared to 2025. Much of that is due to increasing competition from both Eli Lilly and compounding pharmacies that are selling copycat versions of Novo’s branded drugs for a lower price.

Longer term, other large-cap pharma companies are planning to enter the market, and are pitching investors more differentiated weight loss drugs to be able to secure a slice of the market share for themselves.

Novo is hoping CagriSema can beef up future sales, but after the latest trial results, analysts are increasingly doubting its commercial potential.

Novo said it is optimistic about the drug, and that further trials would assess its full weight-loss potential.

The Wegovy pill is another potential growth driver for Novo and had a strong launch. However, it remains to be seen how it will fare if Lilly launches its rival pill, expected to hit the market in the second quarter, and what effects lower prices might have on volumes.

Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.